Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Validation Study of a CT-Based Weighted Rating Scale for Subcortical Ischemic Vascular Disease in Patients with Mild Cognitive Deterioration

Geroldi C.a,b · Galluzzi S.a · Testa C.a · Zanetti O.b · Frisoni G.B.a

Author affiliations

aLaboratory of Epidemiology and Neuroimaging and bAlzheimer’s Unit, IRCCS San Giovanni di Dio – FBF, Brescia, Italy

Related Articles for ""

Eur Neurol 2003;49:193–209

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 11, 2002
Accepted: December 27, 2002
Published online: May 14, 2003
Issue release date: May 2003

Number of Print Pages: 17
Number of Figures: 8
Number of Tables: 4

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE

Abstract

Objectives: Subcortical ischemic vascular disease (SIVD) is frequently associated with cognitive impairment. Rating scales to grade cerebrovascular disease are available, but their sensitivity to the clinical features of mild SIVD is unclear. The aim of the study is to devise and validate a computed tomography (CT)-based visual rating scale sensitive to SIVD in patients with mild cognitive deterioration. Methods: Subjects were 122 consecutive outpatients of a memory clinic (mean age ± SD 77 ± 8 years, 71% females, mean ± SD score of mental state exam 22 ± 3, 61% with clinical dementia rating of 0.5 and 39% of 1). Diffuse leukoaraiosis, fuzzy and patchy lesions, and lacunes were assessed on ordinary CT films and weights were computed based on clinical indicators of SIVD. A continuous score and an ordinal class (0–3) with higher values indicating higher vascular damage were derived. Results: Intraclass correlation coefficients for intra- and interrater reliability of the subcortical vascular score and class ranged from 0.84 to 0.88. Convergent validity versus the scale of Wahlund et al. was good (Spearman’s correlation coefficient between 0.53 and 0.73, p < 0.0005). Known-group validity was assessed versus clinical diagnoses of degenerative (mild cognitive impairment determined by Petersen et al. and NINCDS-ADRDA probable Alzheimer’s disease; n = 58), mixed (possible Alzheimer’s disease with cerebrovascular disease; n = 21), and vascular cognitive impairment (criteria of Erkinjuntti et al. for subcortical vascular dementia and cognitive impairment; n = 43). Patients with degenerative cognitive impairment were more often in the lower subcortical vascular classes (43% in class 0, 43% in class 1, 14% in class 2, and 0% in class 3), while patients with mixed (0, 24, 24, and 52%) and vascular cognitive impairment were in increasingly higher subcortical vascular classes (0, 12, 35, 53%; p < 0.00005). Criterion-related validity was assessed versus clinical indicators of cerebrovascular disease. Hypertension, platelet aggregation inhibitor use, balance, gait, and bradykinesia increased linearly with increasing subcortical vascular class (p for trend <0.02). Conclusions: This rating scale is valid and sensitive to capture different degrees of SIVD associated with mild cognitive deterioration.

© 2003 S. Karger AG, Basel


References

  1. Chui H: Dementia due to subcortical ischemic vascular disease. Clin Cornerstone 2001;3:40–51.
  2. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Roman GC, Chui H, Desmond DW: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23–30.
  3. Erkinjuntti T, Bowler JV, DeCarli CS, Fazekas F, Inzitari D, O’Brien JT, Pantoni L, Rockwood K, Scheltens P, Wahlund LO, Desmond DW: Imaging of static brain lesions in vascular dementia: Implications for clinical trials. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S81–S90.
  4. Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, Moroney JT, Ferris SH, Stern Y, Sachdev PS, Hachinski VC: The cognitive syndrome of vascular dementia: Implications for clinical trials. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S21–S29.
  5. Scheltens P, Erkinjunti T, Leys D, Wahlund LO, Inzitari D, del Ser T, Pasquier F, Barkhof F, Mantyla R, Bowler J, Wallin A, Ghika J, Fazekas F, Pantoni L: White matter changes on CT and MRI: An overview of visual rating scales. European Task Force on Age-Related White Matter Changes. Eur Neurol 1998;39:80–89.
  6. Lopez OL, Becker JT, Jungreis CA, Rezek D, Estol C, Boller F, DeKosky ST: Computed tomography – but not magnetic resonance imaging – identified periventricular white-matter lesions predict symptomatic cerebrovascular disease in probable Alzheimer’s disease. Arch Neurol 1995;52:659–664.
  7. Rezek DL, Morris JC, Fulling KH, Gado MH: Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology 1987;37:1365–1368.
  8. Awad IA, Johnson PC, Spetzler RF, Hodak JA: Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. 2. Postmortem pathological correlations. Stroke 1986;17:1090–1097.
  9. Gerard G, Weisberg LA: MRI periventricular lesions in adults. Neurology 1986;36:998–1001.
  10. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O’Leary D, Fried L: Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3,301 elderly people. The Cardiovascular Health Study. Stroke 1996;27:1274–1282.
  11. Manolio TA, Kronmal RA, Burke GL, Poirier V, O’Leary DH, Gardin JM, Fried LP, Steinberg EP, Bryan RN: Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke 1994;25:318–327.
  12. Charletta D, Gorelick PB, Dollear TJ, Freels S, Harris Y: CT and MRI findings among African-Americans with Alzheimer’s disease, vascular dementia, and stroke without dementia. Neurology 1995;45:1456–1461.
  13. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA: MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 1987;149:351–356.
  14. Liu CK, Miller BL, Cummings JL, Mehringer CM, Goldberg MA, Howng SL, Benson DF: A quantitative MRI study of vascular dementia. Neurology 1992;42:138–143.
  15. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P, European Task Force on Age-Related White Matter Changes: A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318–1322.
    External Resources
  16. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  17. Frisoni GB, Geroldi C, Beltramello A, Bianchetti A, Binetti G, Bordiga G, DeCarli C, Laakso MP, Soininen H, Testa C, Zanetti O, Trabucchi M: Radial width of the temporal horn: A sensitive measure in Alzheimer disease. AJNR Am J Neuroradiol 2002;23:35–47.
  18. Geroldi C, Akkawi NM, Galluzzi S, Ubezio M, Binetti G, Zanetti O, Trabucchi M, Frisoni GB: Temporal lobe asymmetry in patients with Alzheimer’s disease with delusions. J Neurol Neurosurg Psychiatry 2000;69:187–191.
  19. Nicosia F, Alberici A, Benussi L, Gasparini L, Ghidoni R, Mazzoli F, Zanetti O, Frisoni GB, Geroldi C, Binetti G: Analysis of alpha-2-macroglobulin-2 allele as a risk factor in Alzheimer’s disease. Dement Geriatr Cogn Disord 2001:12:305–308.
  20. Magni E, Binetti G, Bianchetti A, Trabucchi M: Mini-Mental State Examination: A normative study in an Italian elderly population. Eur J Neurol 1996;3:198–202.
  21. Morris JC: The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43:2412–2414.
  22. Lawton MP, Brody EM: Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–186.
  23. Mahoney FI, Barthel DW: Functional evaluation: The Barthel Index. Md State Med J 1965;14:61–65.
    External Resources
  24. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1982;17:37–49.
  25. Davignon J, Gregg RE, Sing CF: Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1–21.
  26. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993;43:1467–1472.
  27. Richards M, Marder K, Bell K, Dooneief G, Mayeux R, Stern Y: Interrater reliability of extrapyramidal signs in a group assessed for dementia. Arch Neurol 1991;48:1147–1149.
  28. Dahlbeck JW, McCluney KW, Yeakley JW, Fenstermacher MJ, Bonmati C, Van Horn G 3rd, Aldag J: The interuncal distance: A new RM measurement for the hippocampal atrophy in Alzheimer’s disease. AJNR Am J Neuroradiol 1991;12:931–932.
  29. Early B, Escalona PR, Boyko OB, Doraiswamy PM, Axelson DA, Patterson L, McDonald WM, Krishnan KR: Interuncal distance measurements in healthy volunteers and in patients with Alzheimer disease. AJNR Am J Neuroradiol 1993;14:907–910.
  30. Spector PE: Summated Rating Scale Construction: An Introduction (Quantitative Applications in the Social Sciences). London, Sage Publications, 1992.
  31. McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group. Neurology 1984;34:939–944.
  32. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  33. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L: Cerebral blood flow in dementia. Arch Neurol 1975;32:632–637.
  34. Tinetti ME: Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 1986;34:119–126.
  35. Reuben DB, Siu AL: An objective measure of physical function of elderly outpatients. The Physical Performance Test. J Am Geriatr Soc 1990;38:1105–1112.
  36. Ebel RL: Estimation of the reliability of ratings. Psychometrika 1951;16:407–424.
  37. Bowler JV, Steenhuis R, Hachinski V: Conceptual background to vascular cognitive impairment. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S30–S37.
  38. Pantoni L, Leys D, Fazekas F, Longstreth WT Jr, Inzitari D, Wallin A, Filippi M, Scheltens P, Erkinjuntti T, Hachinski V: Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S49–S54.
  39. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS): Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–175.
  40. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997;277:813–817.
  41. Zijlmans JC, Pasman JW, Horstink MW, Stegeman DF, van’t Hof MA, Poortvliet DJ, Notermans SL, Jonkman EJ: EEG findings in patients with vascular parkinsonism. Acta Neurol Scand 1998;98:243–247.
  42. Tohgi H, Takahashi S, Abe T, Utsugisawa K: Symptomatic characteristics of parkinsonism and the width of substantia nigra pars compacta on MRI according to ischemic changes in the putamen and cerebral white matter: Implications for the diagnosis of vascular parkinsonism. Eur Neurol 2001;46:1–10.
  43. Yamanouchi H, Nagura H: Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke 1997;28:965–969.
  44. Esiri MM: Which vascular lesions are of importance in vascular dementia? Ann NY Acad Sci 2000;903:239–243.
  45. del Ser T, Bermejo F, Portera A, Arredondo JM, Bouras C, Constantinidis J: Vascular dementia. A clinicopathological study. J Neurol Sci 1990;96:1–17.
  46. Goto K, Ishii N, Fukasawa H: Diffuse white-matter disease in the geriatric population. A clinical, neuropathological, and CT study. Radiology 1981;141:687–695.
  47. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H: Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683–1689.
  48. Munoz DG, Hastak SM, Harper B, Lee D, Hachinski VC: Pathologic correlates of increased signals of the centrum ovale on magnetic resonance imaging. Arch Neurol 1993;50:492–497.
  49. Chimowitz MI, Estes ML, Furlan AJ, Awad IA: Further observations on the pathology of subcortical lesions identified on magnetic resonance imaging. Arch Neurol 1992;49:747–752.
  50. Huang K, Wu L, Luo Y: Binswanger’s disease: Progressive subcortical encephalopathy or multi-infarct dementia? Can J Neurol Sci 1985;12:88–94.
  51. Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M: A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773–780.
  52. Esiri MM, Wilcock GK, Morris JH: Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry 1997;63:749–753.
  53. Pullicino P, Benedict RH, Capruso DX, Vella N, Withiam-Leitch S, Kwen PL: Neuroimaging criteria for vascular dementia. Arch Neurol 1996;53:723–728.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 11, 2002
Accepted: December 27, 2002
Published online: May 14, 2003
Issue release date: May 2003

Number of Print Pages: 17
Number of Figures: 8
Number of Tables: 4

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.